{
  "pmcid": "11262731",
  "sha256": "ac84392779350c4eee40aa4543c35fda7a0f44909f60cf22cf3170312495a373",
  "timestamp_utc": "2025-11-09T22:01:33.768449+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.702574235807859,
    "reading_ease": 31.554734716157242,
    "word_count": 229
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Bleselumab for Prevention of Recurrent Focal Segmental Glomerulosclerosis"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this phase 2a, randomised, open-label trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "adult kidney transplant recipients with biopsy-proven primary FSGS were enrolled at 23 sites in Canada and the United States"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to receive bleselumab with tacrolimus and corticosteroids or standard of care (SOC) with tacrolimus, mycophenolate mofetil, and corticosteroids."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates bleselumab, an anti-CD40 monoclonal antibody, for preventing recurrent FSGS (rFSGS)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was rFSGS, defined as proteinuria (protein-creatinine ratio ≥3.0 g/g) with death, graft loss, or loss to follow-up imputed as rFSGS, measured through 3 months posttransplant."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Participants were randomised 1:1"
      },
      "Blinding": {
        "score": 2,
        "evidence": "outcome assessors were blinded"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Sixty-three patients were analysed (bleselumab: 29, SOC: 34)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Sixty-three patients were analysed (bleselumab: 29, SOC: 34)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Bleselumab showed a 40.7% relative decrease in rFSGS occurrence versus SOC (95% CI, −89.8 to 26.8; P = 0.37)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with no deaths reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ClinicalTrials.gov NCT02921789."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: The study was funded by the sponsor."
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}